Business context and reporting period
This is Sunshine Heart, Inc.’s unaudited Form 10-Q for the three months ended March 31, 2012. The request identifies Nuwellis, Inc., but the filing names Sunshine Heart, Inc.; verify the entity and filing match. Sunshine Heart was an early-stage medical-device company developing the C-Pulse Heart System for heart failure. It had no commercial product sales in either comparative quarter.
Financial results and liquidity
| Metric | Q1 2012 | Q1 2011 / prior balance-sheet date |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $4.106 million | $2.934 million |
| Operating loss | $4.106 million | $2.934 million |
| Net loss | $4.081 million | $2.817 million |
| Basic and diluted loss per share | $0.66 | $0.55 |
| Operating cash used | $4.768 million | $2.802 million |
| Cash and cash equivalents | $3.832 million at March 31, 2012 | $6.563 million at December 31, 2011 |
| Total liabilities | $2.049 million at March 31, 2012 | $2.835 million at December 31, 2011 |
Gross profit and margins were zero or not meaningful because there were no sales. The filing reports no debt; liabilities shown are current liabilities, principally accounts payable and accrued compensation. The company raised $2.061 million net through a February private placement. Cash declined $2.731 million during the quarter. No material capital-expenditure commitments or off-balance-sheet arrangements were reported.
Material changes versus the prior comparable period
- Net loss increased by $1.264 million, while operating expenses rose $1.172 million. Selling, general and administrative expense increased $1.298 million to $1.940 million, primarily from stock compensation, professional fees and personnel costs, Nasdaq-listing preparation, audit timing, and European-trial preparation.
- Research and development expense decreased 5.5% to $2.166 million, mainly because of timing of outsourced development work.
- Operating cash use increased by $1.966 million. Interest income fell to $25,000 from $117,000, primarily because average cash balances were lower.
- Cash fell from $6.563 million at year-end to $3.832 million at quarter-end. The February placement issued 256,875 shares and included warrants.
Outlook, risks and unusual items
- Management said available cash was expected to fund operations through substantially all of the first half of 2012, but additional financing would be needed within the next three months. The company depended on raising capital and disclosed that failure to obtain funding could jeopardize its ability to continue as a going concern.
- After reviewing feasibility-trial data, the FDA indicated in March 2012 that the company could proceed with an IDE application. Management expected to submit it in the first half of 2012, complete the pivotal trial in 2015, and did not expect U.S. marketing before 2016. These were forward-looking expectations, not assured outcomes.
- The company anticipated CE Mark approval in mid-2012 and expected European trials to begin in the second half of 2012; commercial timing depended on regulatory approval and trial progress.
- Key risks include financing availability, clinical and regulatory outcomes, successful product development and commercialization, and market acceptance. Management reported effective disclosure controls and no material change in internal control over financial reporting.
- The cover page indicates “No” to whether all required Exchange Act reports had been filed during the preceding 12 months; investors should verify the context and any compliance implications.
Important facts to verify
- Confirm that this Sunshine Heart filing is the intended filing for the requested Nuwellis, Inc.
- Check subsequent financing, cash runway, and any going-concern updates.
- Verify the actual timing and outcomes of the IDE application, pivotal trial, and European regulatory process.
- Review the cover-page response about filing required reports and any related SEC filing history.